Multicenter Selective Lymphadenectomy Trial II (MSLT-II)
A Phase III Multicenter Randomized Trial of Sentinel Lymphadenectomy and Complete Lymph Node Dissection Versus Sentinel Lymphadenectomy Alone in Cutaneous Melanoma Patients With Molecular or Histopathological Evidence of Metastases in the Sentinel Node
Sponsor: National Cancer Institute (NCI)
A NA clinical study on Melanoma, this trial is completed. The trial is conducted by National Cancer Institute (NCI) and has accumulated 15 data snapshots since 2004. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
15 versions recorded-
Sep 2025 — Present [monthly]
Completed NA
-
Sep 2024 — Sep 2025 [monthly]
Completed NA
-
Jul 2024 — Sep 2024 [monthly]
Completed NA
-
Jun 2022 — Jul 2024 [monthly]
Completed NA
Status: Active Not Recruiting → Completed
-
Apr 2022 — Jun 2022 [monthly]
Active Not Recruiting NA
▶ Show 10 earlier versions
-
Sep 2021 — Apr 2022 [monthly]
Active Not Recruiting NA
-
Jan 2021 — Sep 2021 [monthly]
Active Not Recruiting NA
-
Nov 2020 — Jan 2021 [monthly]
Active Not Recruiting NA
-
Nov 2019 — Nov 2020 [monthly]
Active Not Recruiting NA
-
Oct 2019 — Nov 2019 [monthly]
Active Not Recruiting NA
-
Mar 2019 — Oct 2019 [monthly]
Active Not Recruiting NA
-
Jun 2018 — Mar 2019 [monthly]
Active Not Recruiting NA
-
Sep 2017 — Jun 2018 [monthly]
Active Not Recruiting NA
-
Feb 2017 — Sep 2017 [monthly]
Active Not Recruiting NA
Phase: PHASE3 → NA
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE3
First recorded
Sep 2004
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- National Cancer Institute (NCI)
- National Institutes of Health (NIH)
- Saint John's Cancer Institute
For direct contact, visit the study record on ClinicalTrials.gov .